

MARIJUANA

EFFECTS ON HUMAN BEHAVIOR

CONTRIBUTORS

Howard Cappell Charles F. Darley Fonya Lord DeLong Rhea L. Dornbush William G. Drew Robert B. Forney Erich Goode James A. Halikas Glen F. Kiplinger Harry Klonoff Bernard I. Levy Morton D. Low Barbara R. Manno Joseph E. Manno Loren L. Miller Patricia Pliner Jared R. Tinklenberg Abraham Wikler

MARIJUANA

EFFECTS ON HUMAN BEHAVIOR

Edited by LOREN L. MILLER

Laboratories of Behavioral Neurophysiology Department of Psychiatry University of Kentucky Albert B. Chandler Medical Center Lexington, Kentucky



ACADEMIC PRESS

New York San Francisco London 1974 A Subsidiary of Harcourt Brace Jovanovich, Publishers COPYRIGHT © 1974, BY ACADEMIC PRESS, INC. ALL RIGHTS RESERVED. NO PART OF THIS PUBLICATION MAY BE REPRODUCED OR TRANSMITTED IN ANY FORM OR BY ANY MEANS, ELECTRONIC OR MECHANICAL, INCLUDING PHOTOCOPY, RECORDING, OR ANY INFORMATION STORAGE AND RETRIEVAL SYSTEM, WITHOUT PERMISSION IN WRITING FROM THE PUBLISHER.

ACADEMIC PRESS, INC. 111 Fifth Avenue, New York, New York 10003

United Kingdom Edition published by ACADEMIC PRESS, INC. (LONDON) LTD. 24/28 Oval Road, London NW1

Library of Congress Cataloging in Publication Data

Miller, Loren L Marijuana; effects on human behavior.

Includes bibliographies.

Marihuana-Psychological aspects. 1. 2. Marihuana [DNLM: -Physiological effect. Ι. Title. 1. Behavior-Drug effects. 2. Cannabis-Pharmacodynamics. 3. Psychopharmacology. QV109 M648m] 615'.782 BF209.M3M55 74-10216 ISBN 0-12-497050-8

PRINTED IN THE UNITED STATES OF AMERICA

CONTENTS

List of Contributors Preface

xi xiii

Chapter 1

THE LOGISTICS OF MARIJUANA RESEARCH: METHODOLOGICAL, LEGAL, AND SOCIETAL Harry Klonoff

I. Introduction	1
II. Clinical Research Planning	3
III. Clinical Study at the University of British Columbia	10
IV. Driving Research Planning	19
V. Summary	22
References	23

Chapter 2

THE MARIJUANA CONTROVERSY

Abraham Wikler

I.	Introduction	25
II.	Biological Issues	26
III.	Aesthetic Issues	39
IV.	Social Issues	40
	References	42

Chapter 3

MOTOR AND MENTAL PERFORMANCE WITH MARIJUANA: RELATIONSHIP TO ADMINISTERED DOSE OF Δ^9 -TETRAHYDROCANNABINOL AND ITS INTERACTION WITH ALCOHOL

Joseph E. Manno, Barbara R. Manno, Glen F. Kiplinger, and Robert B. Forney

I.	Introduction	46
	Preparation and Calibration of Marijuana	
	Cigarettes for Administration	
	of Uniform Dosage	47
III.	Establishment of Experimental Procedures	49
IV.	Marijuana Dosage Form	55
V.	Motor Performance	56
VI.	Mental Performance and Ataxia	59
VII.	Physiological Reactions to THC and Alcohol	59
VIII.	Subjective Reactions	64
IX.	Significance and Conclusion	69
	References	71

Chapter 4

MARIJUANA AND MEMORY

Charles F. Darley and Jared R. Tinklenberg

I.	Introduction	73
	Purposes of Marijuana-Memory Research	74
	A Working Memory Model	76
	Experimental Tasks and Specific Experiments	
	with Marijuana	78
V.	Locus of the Storage Deficit	88
VI.	Evidence of State-Dependent Retrieval	92
VII.	Alternative Interpretations of Experimental Results	94
VIII.	New Directions and Promising Research	96
IX.	Outlook for Marijuana-Memory Research	99
	References	100

Contents

Chapter 5

A MODEL OF ATTENTION DESCRIBING THE COGNITIVE EFFECTS OF MARIJUANA Fonya Lord DeLong and Bernard I. Levy

I.	ntroduction	103
II.	A Model of Attention	104
III.	Summary	117
	References	117

Chapter 6

PSYCHOLOGICAL AND NEUROPHYSIOLOGICAL EFFECTS OF MARIJUANA IN MAN: AN INTERACTION MODEL

Harry Klonoff and Morton D. Low

I.	Introduction	n]
II.	Methods .]
III.	Results]
IV.	Discussion			 	 								 				J
	References		 														

Chapter 7

CANNABIS: NEURAL MECHANISMS AND BEHAVIOR

Loren L. Miller and William G. Drew

I.	Introduction	158
II.	Cognitive Effects of Cannabis in Man	158
III.	Hippocampus and Memory	160
	Hippocampus and Internal Inhibition	163
V.	Cholinergic System, Memory, and Inhibition	164
VI.	Comparison of Cannabinoids, Anticholinergics, and	
	Hippocampectomy	165
VII.	Evidence That Cannabinoids Exert Actions within the	
	Limbic System	171
VIII.	Evidence That Cannabinoids Exert Actions on Cholinergic	
	Mechanisms	173

IX.	Data Inconsistent with the Cholinergic Hypothesis	175
	Effects of THC on Neuroendocrine Systems	
XI.	Comparison of THC, the Extraadrenal Actions of ACTH,	
	and Hippocampectomy	178
XII.	Summary	181
	References	182

Chapter 8

MARIJUANA AND BEHAVIOR: HUMAN AND INFRAHUMAN COMPARISONS

Loren L. Miller

I.	Introduction	189
II.	Memory and Acquisition	191
III.	Timing Behavior	202
IV.	State-Dependent Learning	206
	Attention and Habituation	
VI.	Summary and Discussion	216
	References	217

Chapter 9

THE LONG-TERM EFFECTS OF CANNABIS USE Rhea L. Dornbush

I.	Introduction	221
II.	Studies of Chronic Use in Created Populations	222
	Studies in Animals	
IV.	Studies of Chronic Use in Existing Populations	228
	Summary	
	References	231

Chapter 10

CANNABIS INTOXICATION: THE ROLE OF PHARMACOLOGICAL AND PSYCHOLOGICAL VARIABLES Howard Cappell and Patricia Pliner

I. Introduction 233

Contents

II.	Recent Evid	ence			 	 	 	235
III.	The Experim	nental I	Program	n	 	 	 	242
IV.	Conclusions				 	 	 	261
	References		• • • • •	• • •		 	 	263

Chapter 11

MARIJUANA USE AND PSYCHIATRIC ILLNESS James A. Halikas

I.	Statement of the Problem	265
II.	Pitfalls in Marijuana Research	267
III.	Psychiatric Syndromes Described in Association with	
	Marijuana Use	277
IV.	Correlations of Marijuana Use with Psychiatric Illness	289
	Conclusion	297
	References	29 9

Chapter 12

MARIJUANA USE AND THE PROGRESSION TO DANGEROUS DRUGS

Erich Goode

I.	Introduction	303
II.	Logical Issues—Descriptive Studies	305
III.	Methodological Issues-Descriptive Studies	313
IV.	Logical Issues—Causal Mechanisms	320
V.	Methodological Issues-Causal Mechanisms	327
	References	

Chapter 13

MARIJUANA AND HUMAN AGGRESSION Jared R. Tinklenberg

I.	Introduction
П.	Basic Considerations
III.	Sources and Limitations
	Laboratory Data
	Field Studies of Marijuana and Human Aggression
	References

Chapter 14

EFFECTS OF MARIJUANA ON DRIVING IN A **RESTRICTED AREA AND ON CITY STREETS:** DRIVING PERFORMANCE AND PHYSIOLOGICAL CHANGES

Harry Klonoff

I. Introdu																	
I. Method																	
I. Results		 	 					 									
7. Discussi	on	 	 					 									
7. Conclus	ion	 	 					 									
Referen																	

Subject Index

399

LIST OF CONTRIBUTORS

Numbers in parentheses indicate the pages on which the authors' contributions begin.

- Howard Cappell (233), Addiction Research Foundation, Toronto, Ontario, Canada
- Charles F. Darley (73), Department of Psychiatry, Stanford University School of Medicine, Stanford, California, and Veterans Administration Hospital, Palo Alto, California
- Fonya Lord DeLong (103),* Department of Psychology, George Washington University, Washington, D.C.
- Rhea L. Dornbush (221), Department of Psychiatry, New York Medical College, New York, New York
- William G. Drew (157), Department of Psychiatry, University of Kentucky, Lexington, Kentucky
- Robert B. Forney (45), Department of Toxicology, Indiana University Medical Center, Indianapolis, Indiana
- Erich Goode (303), Department of Sociology, State University of New York, Stony Brook, New York
- James A. Halikas (265), Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri
- Glen F. Kiplinger (45), The Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana
- Harry Klonoff (1,121,359), Division of Psychology, Department of Psy-

* Present address: 4840 Glenbrook Rd., N.W., Washington, D.C.

chiatry, University of British Columbia, Vancouver, British Columbia, Canada

- Bernard I. Levy (103), Department of Psychology, George Washington University, Washington, D.C.
- Morton D. Low (121), Department of Neurology, University of British Columbia, Vancouver, British Columbia, Canada
- Barbara R. Manno (45), Veterans Administration Hospital, Shreveport, Louisiana
- Joseph E. Manno (45), Department of Pharmacology and Therapeutics, Louisiana State University School of Medicine, Shreveport, Louisiana
- Loren L. Miller (157,189), Laboratories of Behavioral Neurophysiology, Department of Psychiatry, University of Kentucky, Albert B. Chandler Medical Center, Lexington, Kentucky
- Patricia Pliner (233), Department of Psychology, Erindale College, University of Toronto, Clarkson, Ontario, Canada
- Jared R. Tinklenberg (73,339), Department of Psychiatry, Stanford University School of Medicine, Stanford, California, and Veterans Administration Hospital, Palo Alto, California
- Abraham Wikler (25), Department of Psychiatry, University of Kentucky Medical Center, Lexington, Kentucky

PREFACE

The use of marijuana in the United States during the past decade has burgeoned. Yet, until recently, a paucity of objective evidence existed pertaining to the behavioral and physiological actions of the drug. Although efforts have been made recently to research the marijuana problem, the use of the drug has increased at such an alarming rate that it is doubtful that such efforts will keep pace with the discovery of new social consequences concerning its continued use. In addition, much research to date has been hampered by political and social issues surrounding the use of marijuana on a widespread basis. Whether or not marijuana ingestion has long range detrimental effects on the mental and physical health of members of our society is certainly a polemic question with no final answers but only more questions. Unfortunately, debating the relative merits of using or not using marijuana has in numerous instances clouded an important issue: that of scientifically determining in a systematic and objective manner the effects of this agent on human behavior. Eschewing the use of marijuana without an unbiased evaluation of the drug's actions and at the same time offering moralistic arguments makes no more sense than promoting the use of the drug on the basis of subjective evaluations such as "it makes me feel more creative" and "insightful" or "more wellrounded." Numerous types of arguments for or against its consumption can be contrived, but most suffer from speciosity and from what Harry Stack Sullivan has termed paritaxical reasoning.

Although a plethora of research on marijuana has been conducted in the past three to four years, the majority of it has been devoted to defining and characterizing such variables as the pharmacological and chemical properties of cannabis and its basic physiological effects. Surprisingly, systematic research concerning the effects of marijuana on human behavior is minimal compared with some of the above-mentioned research areas when in fact this area is of vital importance from a scientific as well as social point of view.

This book attempts to synthesize much of the existing experimentation concerning the acute and chronic effects of marijuana and its derivatives on human behavior.

Loren L. Miller

MARIJUANA

EFFECTS ON HUMAN BEHAVIOR

This page intentionally left blank

Chapter 1

THE LOGISTICS OF MARIJUANA RESEARCH: METHODOLOGICAL, LEGAL, AND SOCIETAL

HARRY KLONOFF

I.	Introduction	1
II.	Clinical Research Planning	3
	A. Strategy and Tactics for Clinical Research on Marijuana	3
	B. A Model for Marijuana Clinical Research	6
	C. A Model for Self-Reporting of Marijuana Experiences	9
III.	Clinical Study at the University of British Columbia	10
	A. Criteria for Volunteers and Screening Procedure	10
	B. Background Characteristics of Subjects	11
	C. Experimental Design and Examination Procedure	11
	D. Marijuana and Placebo	12
IV.	Driving Research Planning	19
	A. Strategy and Tactics for Research on Marijuana and	
	Driving	19
	B. A Model for Driving and Marijuana	20
v.	Summary	22
	References	23

I. INTRODUCTION

The progress of science is the work of creative minds. Every creative mind that contributes to scientific advance works, however, within two limitations. It is limited, first, by ignorance, for one discovery waits upon that other which opens the way to it. Discovery and its acceptance are, however, limited also by the habits of thought that pertain to the culture of any region and period, that is to say, by the Zeitgeist: an idea too strange or preposterous to be thought in one period of western civilization may be readily accepted as true later. Slow change is the rule—at least for the basic ideas. On the other hand, the more superficial fashions as to what is important, what is worth doing and talking about, change much more rapidly, depending partly on discovery and partly on the social interaction of the wise men most concerned with the particular matter in hand—the cross-stimulation of leaders and their followers, of protagonists and their antagonists (Boring, 1950).

This chapter is directed to those scientists and researchers who are willing to persevere in their search for explanation, understanding, and prediction, in spite of *Zeitgeist* protagonists and antagonists of marijuana usage.

Is the drug problem of today really as unique and mysterious as many would have us believe? From a historical perspective, the use of mindaltering agents may be as timeless as man, the motivation in all probability deriving from the need to make life more pleasurable or from the desire to diminish the stress of human existence. The Sumerians, 7000 years ago, described on clay tablets the cultivation and preparation of opium (Neligan, 1927). Alcohol, with all its distressing consequences, is described in the Old Testament. The Chinese, 4000 years ago, used cannabis as a remedy (Nahas, 1973). In turning from the historical to the contemporary, a National Commission on Marijuana and Drug Abuse survey estimated that the total number of persons who have used marijuana in the United States may exceed 24 million (National Institute of Mental Health, 1972). Fejer et al. (1971), in surveying students in grades 7, 9, 11, 12, and 13, found that marijuana use increased 173% in Toronto between 1968 and 1970, and 162% in Halifax between 1969 and 1970. It should also be noted that in addition to nonprescribed mind-altering agents ingested in North American society there has been an explosion of prescribed psychotropic drugs (major tranquilizers, minor tranquilizers, antidepressants, stimulants, sedatives, and hypnotics). Between 1958 and 1967, there was a 65% increase in new psychotropic drug prescriptions filled in the United States; in 1967, psychotropic drugs accounted for 17% or 178 million prescriptions; mixture of psychotropic and nonpsychotropic drug prescriptions was 275 million or 25% of all prescriptions written; extent of use was 133.1 new and refill prescriptions for every 100 of adult population; one-quarter of all adults took a psychotropic agent in the 12 months preceding the survey; prescribing occurs in the over 20 age group, principally ages 40 to 59; and females account for 67% of all psychotropic drug usage (Balter and Levine, 1969).

Le Dain (1973) lists the following causes which interact to predispose and encourage the individual to engage in nonmedical drug use: per-

1. The Logistics of Marijuana Research

sonality of the user; his close personal relations—family, school, and peer group; social and economic conditions; and the general attitude of society toward drug use as reflected by advertising media and the practices of the adult population.

Some of the hysteria surrounding marijuana use is abating and the climate for research on marijuana is improving. But those concerned with social action and legislative change are still searching for credible information, and it would seem that there are four streams of relevant investigation that might help to bridge the information gap. The first area of investigation is that of the acute effects of marijuana. Researchers have been active in this area and the acute effects of marijuana have been documented in Canadian studies (Le Dain Commission, 1972, 1973; Klonoff, 1973a,b; Klonoff et al., 1973; Low et al., 1973; Marcus et al., 1974), as well as numerous studies in the United States (National Institute of Mental Health, 1972). The second area is that of the effects of marijuana on driving in a real life situation, and only two studies have been reported in this area (Le Dain Commission, 1972; Klonoff, Chapter 14). The third area is that of the chronic use of marijuana, particularly heavy chronic use, and in a relevant culture. There is no reported study in this area that can withstand critical scrutiny. The fourth area would involve a consideration of the effects on society if two mindaltering agents (marijuana and alcohol, rather than only alcohol) were available on demand, possibly using the ecosystems approach of Fisher and Strantz (1972).

Regarding the fourth area of investigation, Milner (1973) outlines some of the relevant variables that would be worthy of investigation before moving into the legalization of marijuana, and these are as follows: adverse effects, driving hazards, multiple drug use, incorrect evaluation, consumer culture, alcohol and marijuana, example to children, rights of the less-privileged, prejudiced assessments, community testing, legal control difficulties, social group alienation problems, regard for the law, and social goals.

II. CLINICAL RESEARCH PLANNING

A. Strategy and Tactics for Clinical Research on Marijuana

Weil *et al.* (1968) pointed out that research on marijuana is fraught with a large number of legal and attitudinal hurdles and obstacles. The situation they described still obtains today. Accordingly it might be helpful to provide first-hand information and data regarding the nature of such obstacles and, even more important, the ways and means of meeting the necessary demands in order to embark on marijuana research. Figure 1 outlines the channels—university, medicolegal, funding, Food and Drug, and law enforcement—that one must go through before beginning a systematic inquiry on marijuana.




Fig. 1. Channels for initiating research on marijuana.

The process of endorsement begins with the university human experimentation committee. The human experimentation committee at the University of British Columbia passes on the proposed research and certifies that the procedures planned are acceptable on ethical grounds and, in particular, that: (a) the safety, welfare, and rights of the subject(s) are adequately protected; (b) the amount and kind of information communicated to the subject(s) is appropriate in order to secure informed consent* within the best definition of that term; (c) suitable precautions are taken to minimize risks; and (d) the subject is made aware that he has the right to withdraw from the research at any time. In addition, the matter of confidentiality regarding the identity and data of the volunteers must be made explicit, and such confidentiality must be maintained by agreement with the various levels of law enforcement. It should be stressed that human experimentation committees are concerned with the ethical and legal aspects and implications of the proposed research and not with the scientific credibility of the research. The researchers on marijuana at the University of British Columbia obtained approval from a Faculty of Medicine human experimentation committee, and subsequently from a more general university human experimentation committee.

As the research project was to be carried out in the University hospital (Health Sciences Centre), University of British Columbia, as well as the Vancouver General Hospital, it was necessary to obtain the approval from the University administration, specifically, the President of the University and the Board of Governors of the University, as well as from the Vancouver General Hospital administration, specifically, the Medical Board and the Board of Trustees of the Vancouver General Hospital. University and hospital administrations, before endorsing the project, requested their respective solicitors to review the proposals as submitted and to draw up a release and consent form as well as an acknowledgment and certificate form.

The release and consent form made explicit the following: that information had been provided regarding the proposed experiment; the nature, expected duration, and means of administration of the marijuana; potential risks; the nature of supervision during the experiment; freedom to withdraw; assurance that an offence was not being committed against the laws of Canada; and release of the University and the Vancouver General Hospital and their respective staffs from liability. The release and consent form was signed by the volunteer before participating in the project and was witnessed and then endorsed by a physician on the project.

The acknowledgment and certificate form was signed by the volunteer

• Informed consent is defined within the terms of reference of the Declaration of Helsinki-Recommendations Guiding Doctors in Clinical Research (1964).